[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630857":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":25,"locations":24,"responsibleParty":35,"collaborators":24,"id":37,"slug":38,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":24,"eligibilityCriteria":43,"healthyVolunteers":39,"sex":44,"minAge":45,"maxAge":46,"enrollmentInfo":47,"targetDuration":24,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":58,"overallStatus":61,"whyStopped":24,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":24},{"fullName":5,"class":6},"Immunocore Ltd","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Single Ascending Dose","EXPERIMENTAL","Participants receive single ascending doses of IMC-S118AI.",[13],"Biological: IMC-S118AI",{"label":15,"type":10,"description":16,"interventionNames":17},"Multiple Ascending Dose","Participants receive multiple ascending doses of IMC-S118AI.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"BIOLOGICAL","IMC-S118AI","IMC-S118AI solution for infusion\u002Finjection",[15,9],null,[26,31],{"name":27,"role":28,"phone":29,"phoneExt":24,"email":30},"Immunocore Medical Information","CONTACT","844-466-8661","medical.information@immunocore.com",{"name":32,"role":28,"phone":33,"phoneExt":24,"email":34},"Immunocore Medical Information EU","+00 800-744-51111","medinfo.eu@immunocore.com",{"type":36,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100630857","phase-1-study-of-imc-s118ai-in-type-1-diabetes-100630857",false,"NCT07493122","Study of IMC-S118AI in Type 1 Diabetes","A Dose-Escalation Study Evaluating the Safety and Pharmacokinetics of IMC-S118AI in HLA-A*02:01-Positive Participants With Type 1 Diabetes","Inclusion Criteria:\n\n* Body mass index (BMI): 18 to 25 kg\u002Fm2\n* History of a diagnosis of T1D\n* HLA type: HLA-A\\*02:01\n* Shows signs of remaining beta-cell function\n\nExclusion Criteria:\n\n* Non-T1D (type 2 diabetes, monogenic diabetes, and secondary diabetes)\n* History of recurrent hypoglycaemia due to non-compliance with insulin regimens\n* Prior treatment with immunomodulating therapy for T1D\n* Have a history of cardiovascular disease or impaired cardiac function\n* Current diagnosis of a malignancy or any history of malignancy","ALL","18 Years","45 Years",{"count":48,"type":49},154,"ESTIMATED","INTERVENTIONAL",[52],"PHASE1","This is a first-in-human (FIH) study designed to assess the safety, tolerability, and pharmacokinetic (PK) profile of IMC-S118AI in single-ascending dose (SAD) and multiple-ascending dose (MAD) regimens. This study will potentially also explore the effects of multiple-dosing regimens on preservation of beta-cell function in Stage 3 Type 1 diabetes.",[55,56,57],"Type 1 Diabetes","Type 1 Diabetes (T1D)","Diabetes Type 1",[59,60],"diabetes","type 1","NOT_YET_RECRUITING","2026-03-19",{"date":64,"type":65},"2026-03-25","ACTUAL",{"date":67,"type":49},"2026-04",{"date":69,"type":49},"2030-11",{"name":5,"class":6}]